Heather H. Cheng, Ph.D.
Affiliations: | 2005 | University of Washington, Seattle, Seattle, WA |
Area:
Microbiology Biology, Molecular Biology, Animal Physiology Biology, Veterinary Science BiologyGoogle:
"Heather Cheng"Parents
Sign in to add mentor| Julie Overbaugh | grad student | 2005 | University of Washington | |
| (Envelope and receptor determinants for infection by an immunodeficiency -associated feline leukemia virus.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chen N, McGrath CB, Ericsson CI, et al. (2024) Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology |
| Loeb S, Cheng HH, Paller CJ, et al. (2024) Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. Prostate Cancer and Prostatic Diseases |
| Zhao JL, Antonarakis ES, Cheng HH, et al. (2023) Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). British Journal of Cancer |
| Paller CJ, Barata PC, Lorentz J, et al. (2023) PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. The Prostate |
| Schaeffer EM, Srinivas S, Adra N, et al. (2023) Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 1067-1096 |
| Madan RA, Karzai F, VanderWeele DJ, et al. (2023) Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301502 |
| Higano CS, Cheng HH. (2023) Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out? Current Opinion in Urology. 33: 396-403 |
| Herberts C, Wyatt AW, Nguyen PL, et al. (2023) Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 43: e390384 |
| Gillessen S, Bossi A, Davis ID, et al. (2023) Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer (Oxford, England : 1990). 185: 178-215 |
| Cheng HH, Sokolova AO, Gulati R, et al. (2023) Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. Jco Precision Oncology. 7: e2200104 |